Work

Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-204887

Authors: Bingcheng Liu, Ying Wang, Kaiqi Liu, Yan Li, Qiuyun Fang, Yuntao Liu, Xiaoyuan Gong, Chunlin Zhou, Benfa Gong, Guangji Zhang, Shaowei Qiu, Hui Wei, Yingchang Mi, Jianxiang Wang

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405038186

Cites:

Cited by:

Related to: 10